Discovery of Pyridazinopyridinones as Potent and Selective p38 Mitogen-Activated Protein Kinase Inhibitors
Journal of Medicinal Chemistry2010Vol. 53(17), pp. 6398–6411
Citations Over TimeTop 25% of 2010 papers
Bin Wu, Huiling Wang, Liping H. Pettus, Ryan P. Wurz, Elizabeth M. Doherty, Bradley Henkle, Helen J. McBride, Christiaan J. M. Saris, Lu Min Wong, Matthew Plant, Lisa Sherman, Matthew R. Lee, Faye Hsieh, Andrew S. Tasker
Abstract
The p38 mitogen-activated protein kinase (MAPK) plays an important role in the production of proinflammatory cytokines, making it an attractive target for the treatment of various inflammatory diseases. A series of pyridazinopyridinone compounds were designed as novel p38 kinase inhibitors. A structure-activity investigation identified several compounds possessing excellent potency in both enzyme and human whole blood assays. Among them, compound 31 exhibited good pharmacokinetic properties and showed excellent selectivity against other related kinases. In addition, 31 demonstrated efficacy in a collagen-induced arthritis disease model in rats.
Related Papers
- → The Role of MAP Kinases in Trauma and Ischemia–Reperfusion(2004)27 cited
- → Structure of MAPKs(2004)24 cited
- → Role of redox status on the activation of mitogen-activated protein kinase cascades by NSAIDs(2002)22 cited
- → The Role of MAP Kinases in Trauma and Ischemia–Reperfusion(2004)11 cited
- → Effect of Angiotensin III on ERK1/2 and p38 mitogen activated protein (MAP) kinases in Wistar rat VSMCs(2015)